Pfizer beats earnings estimates, raises outlook on cost cuts and smaller-than-feared drop in Covid drug sales

The pharmaceutical giant’s quarterly results also benefited from a smaller-than-feared drop in sales for its Covid antiviral pill Paxlovid.
source